18 Hospital Physician Board Review Manual www.turner-white.com
seizures during follow-up of patients treated for primary
brain tumors. Neurology 2005;65:212–5.
15. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med
1989;87:505–10.
16. Vecht CJ, Wagner GL, Wilms EB. Interactions between
antiepileptic and chemotherapeutic drugs. Lancet Neurol
2003;2:404–9.
17. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter:
anticonvulsant prophylaxis in patients with newly diagnosed
brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology
2000;54:1886–93.
18. Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci
2003;30:106–12.
19. Glantz MJ, Cole BF, Friedberg MH, et al. A randomized,
blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996;46:985–91.
20. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in
metastatic brain tumors: a randomized study of doses of 4,
8, and 16 mg per day. Neurology 1994;44:675–80.
21. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy
plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
22. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro
Oncol 2001;3:193–200.
23. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003;145: 5–10.
24. Kreth FW, Berlis A, Spiropoulou V, et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults.
Cancer 1999;86:2117–23.
25. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate
analysis of 416 patients with glioblastoma multiforme:
prognosis, extent of resection, and survival. J Neurosurg
2001;95:190– 8.
26. Sanai N, Polley MY, McDermott MW, et al. An extent of
resection threshold for newly diagnosed glioblastomas. J
Neurosurg 2011;115: 3–8.
27. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection
for recurrent glioblastoma on overall survival: clinical article.
J Neurosurg 2012;117:1032–8.
28. Chaichana KL, Zadnik P, Weingart JD, et al. Multiple resections for patients with glioblastoma: prolonging survival. J
Neurosurg 2013;118:812–20.
29. Fadul C, Wood J, Thaler H, et al. Morbidity and mortality of
craniotomy for excision of supratentorial gliomas. Neurology
1988;38:1374–9.
30. Westphal M, Ram Z, Riddle V, et al. GLIADEL® Wafer in
initial surgery for malignant glioma: long-term follow-up
of a multicenter controlled trial. Acta Neurochir 2006;148:
269–75.
31. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection
of malignant glioma: a randomised controlled multicentre
phase III trial. Lancet Oncol 2006;7:392–401.
32. Jack CR Jr, Thompson RM, Butts RK, et al. Sensory motor
cortex: correlation of presurgical mapping with functional
MR imaging and invasive cortical mapping. Radiology
1994;190:85–92.
33. Knauth M, Wirtz CR, Tronnier VM, et al. Intraoperative
MR imaging increases the extent of tumor resection in
patients with high-grade gliomas. AJNR Am J Neuroradiol
1999;20:1642–6.
34. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for
newly diagnosed malignant glioma in adults: a systematic
review. Radiother Oncol 2002;64:259–73.
35. Kita M, Okawa T, Tanaka M, Ikeda M. [Radiotherapy of malignant glioma--prospective randomized clinical study of whole
brain vs local irradiation]. Gan No Rinsho 1989;35:1289–94.
36. Shapiro WR, Green SB, Burger PC, et al. Randomized trial
of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group
Trial 8001. J Neurosurg 1989;71: 1–9.
37. Chang CH, Horton J, Schoenfeld D, et al. Comparison of
postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy
Oncology Group and Eastern Cooperative Oncology Group
study. Cancer 1983;52:997–1007.
38. Nelson DF, Diener-West M, Horton J, et al. Combined
modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term
follow-up: a joint study of the Radiation Therapy Oncology
Group and the Eastern Cooperative Oncology Group. NCI
Monogr 1988:279–84.
39. Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy
and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007;5:894–902, 907–15.
40. Brada M, Judson I, Beale P, et al. Phase I dose-escalation
and pharmacokinetic study of temozolomide (SCH 52365)
for refractory or relapsing malignancies. Br J Cancer
1999;81:1022–30.
41. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial
of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Br J Cancer 1992;65:287–91.
42. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II
